• L N Tremblay, R H Hyland, B D Schouten, and P J Hanly.
• Department of Medicine, Wellesley Hospital, University of Toronto, Ontario.
• Clin Invest Med. 1995 Feb 1;18(1):19-24.

AbstractA 5-y (1987-1992) retrospective chart review assessed the survival of patients with acute myelogenous leukemia (AML) who required intubation/ventilatory support in the intensive care unit (ICU). Thirty-two patients were identified, average age 52 +/- 19 (range 14-82) y. Seven patients had undergone bone marrow transplantation for AML 2 weeks to 4 months prior to admission. Of the remaining 25 patients, 16 received chemotherapy prior to admission, 6 started or continued chemotherapy in the ICU, and 3 patients did not receive any chemotherapy. The Apache II score, which quantifies illness severity, on admission to the ICU was 32.5 +/- 8.8. The average length of stay was 7.4 d. Twenty-nine patients had diffuse pulmonary infiltrates on admission, 2 patients had large pleural effusions, and 1 patient had severe bronchospasm with a clear chest X-ray. The average PaO2/FiO2, when first stabilized on mechanical ventilation, was 204 +/- 83. Of the 32 patients, 28 died in the ICU, and 3 died shortly after withdrawal of aggressive therapy and discharge to the ward. A single patient survived the hospital admission but died 4 months later at home. The observed vs. the predicted ICU mortality determined by Knaus' method, was significantly greater even for those with lower Apache II scores. Acute myelogenous leukemia patients had a greater mortality than 2 other intubated patient populations in our ICU admitted during the same time period, a group of 126 consecutive admissions and 53 patients with connective tissue disease. The latter 2 control groups only included patients requiring mechanical ventilation. We conclude that AML patients who require ventilatory support for acute respiratory failure rarely survive their ICU admission.

23 keywords...

hide…